Close

CPIC® Guideline for G6PD

Most recent guideline publication:

Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022)

Tables  provided in the main manuscript of the guideline:

Table 1. Assignment of predicted G6PD phenotype based on genotype
Table 2. Drug-specific risk level and associated strength of recommendation for patients with G6PD deficiency
Table 3. Recommended therapeutic use of high risk drugs in relation to G6PD phenotype
Table 4. Recommended therapeutic use of medium risk drugs in relation to G6PD phenotype
Table 5. Recommended therapeutic use of low-to-no risk drugs in relation to G6PD phenotype
Table 6. Recommended therapeutic use of primaquine in relation to G6PD phenotype

Supplement to: Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype (August 2022)

Tables included in the supplementa:

Table S1. Evidence linking G6PD deficiency to drug-induced hemolysis
Table S2. Association between allelic variants and G6PD activity as defined by the world health organization
Table S3. Summary of select regulatory agency warnings for medication use in patients with G6PD deficiency
G6PD allele definition table
G6PD allele functionality table
G6PD frequency table
G6PD diplotype-phenotype table
Gene resource mapping

G6PD
Drug resource mapping

aminosalicylic acid
aspirin
chloramphenicol
chloroquine
ciprofloxacin
dapsone
dimercaprol
doxorubicin
furazolidone
glyburide
hydroxychloroquine
mafenide
methylene blue
nalidixic acid
nitrofurantoin
norfloxacin
ofloxacin
pegloticase
phenazopyridine
primaquine
quinine
rasburicase
sulfadiazine
sulfadimidine
sulfamethoxazole / trimethoprim
sulfanilamide
sulfasalazine
sulfisoxazole
tafenoquine
tolbutamide
toluidine blue
vitamin c
vitamin k
Clinical decision supportb:
G6PD consult

Pre- and post-test alerts:
aminosalicylic acid
aspirin
chloramphenicol
chloroquine
ciprofloxacin
dapsone
dimercaprol
doxorubicin
furazolidone
glyburide
hydroxychloroquine
mafenide
methylene blue
nalidixic acid
nitrofurantoin
norfloxacin
ofloxacin
pegloticase
phenazopyridine
primaquine
quinine
rasburicase
sulfadiazine
sulfadimidine
sulfamethoxazole / trimethoprim
sulfanilamide
sulfasalazine
sulfisoxazole
tafenoquine
tolbutamide
toluidine blue
vitamin c
vitamin k

aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables (https://www.pharmgkb.org/page/pgxGeneRef) that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.

bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.

2014 guideline: